Drugs / Colon GVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02981524 | May 2017 → Mar 2018 | colorectal cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Colon GVAX | “Colon GVAX is an allogeneic, whole-cell, granulocyte-macrophage colony-stimulating factor -secreting cellular immunotherapy that induces T-cell immunity against...” PMID 31876399 ↗ Dec 2019 |
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02981524 ↗ |
| Route | Other | “GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting” NCT02981524 ↗ |